NCT02545465 (CAPTURE) is a clinical trial of Riociguat (Adempas, BAY63-2521) in Hypertension, Pulmonary, sponsored by Bayer.

Who is sponsoring NCT02545465?

NCT02545465 is sponsored by Bayer.

What drugs are being tested in NCT02545465?

Interventions in NCT02545465: Riociguat (Adempas, BAY63-2521).

What condition does NCT02545465 study?

NCT02545465 studies Hypertension, Pulmonary.

Is NCT02545465 still recruiting?

NCT02545465 is currently completed. Last updated 24 May 2017.

Last reviewed 2017-05-24 · How we verify

NCT02545465: CAPTURE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice

Completed Last updated 24 May 2017

What this trial tests

trial testing Riociguat (Adempas, BAY63-2521) in Hypertension, Pulmonary in 125 participants. Completed in 31 August 2016.

Timeline

15 September 2015

Primary endpoint
31 May 2016

31 August 2016

Quick facts

Lead sponsor	Bayer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	125
Start date	15 September 2015
Primary completion	31 May 2016
Estimated completion	31 August 2016
Sites	7 locations across Colombia, Japan, Belgium, Sweden, Germany, Canada, Turkey (Türkiye)

Drugs / interventions tested

Riociguat (Adempas, BAY63-2521) — full drug profile →

Conditions studied

Hypertension, Pulmonary — all drugs for Hypertension, Pulmonary →

Sponsor

Bayer — full company profile →

Who can join

Eligibility, any sex, with Hypertension, Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice. In addition, this study will describe patient demographics and reason for switching

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
Gall H, Vachiéry JL, Tanabe N, Halank M, et al · · 2018 · cited 12× · PMID 29470642 · DOI 10.1007/s00408-018-0100-3

Verify or expand the search:

Other trials of Riociguat (Adempas, BAY63-2521)

Trials testing the same drug.

NCT04813926 — A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patien · completed
NCT02891850 — Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy · Phase 4 · completed
NCT02562235 — Riociguat in Children With Pulmonary Arterial Hypertension (PAH) · Phase 3 · active not recruiting
NCT02283762 — Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis · Phase 2 · completed
NCT02170025 — Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients · Phase 2 · terminated

Other recruiting trials for Hypertension, Pulmonary

Currently open trials in the same condition.

NCT07087613 — Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG · recruiting
NCT06814145 — Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) · Phase 2 · recruiting
NCT05867914 — Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD · NA · active not recruiting
NCT05719415 — Functional Pulmonary Capillary Surface Area in BPA for CTEPH · NA · recruiting
NCT05179876 — A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no O · Phase 3 · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02545465 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 24 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02545465.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing